Pfizer Global Medical Grants – RFP in Nonalcoholic Steatohepatitis (NASH)

Well-being, Health and Biomedical Discovery


Academic Unit: inquire with unit

Memorial Deadline: Monday 18th, December 2023

External Deadline: Thursday 4th, January 2024


Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Date RFP Issued: September 5, 2023

Geographic Scope: Global

Clinical Area: Nonalcoholic steatohepatitis (NASH)

Link to full RFP: 2023/2024 Global NASH ASPIRE

Application Due Date: January 4, 2024

Specific Area of Interest: The NASH ASPIRE program will evaluate submitted research proposals that cover areas in basic, clinical, and translational sciences. Innovative, feasible, rigorous research proposals with the potential of high impact in advancing the learning about NASH will be prioritized.

The following are the main areas of priority with high unmet needs.

In adult patients with NASH:

  • – Biopsy-confirmed NASH prevalence, clinical outcomes, and healthcare utilization
  • – Innovations in the use of non-invasive tools in the care of patients with NASH
  • – Understanding genetic drivers of NASH and identification of risk factors for disease progression in NASH
    – Real world evidence on current unmet need in patients with NASH and type 2 diabetes and/or obesity
  • Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Jessica Romano, Grant Officer (


Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: September 11, 2023